PRKDC and non-small cell lung carcinoma: As shown, the mTOR kinase inhibitor AZD2014 [30] or the DNA-PK inhibitor NU7026 [31–33] induced moderate but significant cytotoxicity in primary human NSCLC cells, causing viability CCK-8 reduction (Fig. 4D) and cell death (Fig. 4E) in pCan1 and pCan2 primary cells.